📣 Adjuvant alectinib in ALK(+) NSCLC
NEJM
(full report of interim analysis of ALINA trial #ESMO23 )

✅Significantly improved disease-free survival compared with ChT

➡️completely resected, stage IB (tumors ≥4 cm), II, or IIIA
➡️alectinib (600 mg twice daily) for 24 mo vs…

Aún estáis a tiempo para inscribiros al próximo #CodingLungCancer #EGFR del 24 Abril ; curso online gratuito de formación de biomarcadores en #cancerpulmon #NSCLC .

Info e inscripción 👇🏻

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM

astrazeneca.com/media-centre/p…

🧬🧪Have you ever identify a potential germline alteration in the results of a liquid biopsy?

Check out our latest review about incidental PGV, now published in British Journal of Cancer

bit.ly/43R0i1J

Laura Mezquita
Hospital Clínic
International Society of Liquid Biopsy

Meta-analysis on Neoadjuvant Chemo-IO for NSCLC ⁦⁦JAMA Oncology⁩ Neoadjuvant ChemoIO better outcomes vs adjuvant for OS HR 0.65, EFS HR 0.59 (HR 0.74 among pts with PD-L1 expression < 1%). jamanetwork.com/journals/jamao…

Sotorasib did not improved overall survival and the benefit in PFS was modest (if any) compared to docetaxel. Let’s see how adagrasib performs in this setting, with more side effects expected than sotorasib. Really eager to see the details!! #LCSM news.bms.com/news/details/2…

😂😂😂😂😂

El #CLÍNIC ha incorporat al seu pla estratègic l’atenció a l’etapa final de vida amb suport físic, emocional, social i espiritual per a pacients i familiars.

Aquest reportatge de La Vanguardia ho explica 👇👇👇

#ELCC24 Poster updating TROPION-Lung01, phase III of datopotamab deruxtecan (Trop2 ADC) vs docetaxel. Better outcomes in non-squamous NSCLC: PFS 5.5 vs 3.6m (HR 0.63), OS 13.4m vs 11.4m (HR 0.79, interim, ns). All grade ILD rate 8%, all grade stomatitis in 57%. IASLC ESMO - Eur. Oncology

Don't miss this essential read! 📖 Pasi Jänne & colleagues Dana-Farber delve into a crucial topic: #LungCancer in non-smokers. Published in NatureRevClinOncol, it's a must-read
#LCSM . Check it out!
nature.com/articles/s4157…

25 Posts Not To Miss From ELCC 2024
oncodaily.com/41993.html
Dr. Antonio Calles 🫁🚭 Giannis Mountzios Stephen V Liu, MD Julien Mazieres Alfredo Addeo MD Jennifer C. King, PhD Eric K. Singhi, MD Mariana Brandao Charu Aggarwal, MD, MPH, FASCO Gerry Hanna Xiuning Le MD PhD Alona Zer giuseppe viscardi Noemi Reguart Jarushka Naidoo Cecilia Pompili MD PhD FACS #OncoDaily

#ELCC24 Every great play has a grand-finale!!😄 Congratulations to the heroic panelists of the last - but fascinating - session on new molecular pathways and Biomarkers !
Sanjay Popat Noemi Reguart Dr. Antonio Calles 🫁🚭

#ELCC24 : High rates of adverse events in the experimental setting seem to limit the potential of #ADCs for patients with #NSCLC  

#ESMODailyReporter 👉 ow.ly/r3cf50R0hnV

Jarushka Naidoo

#ELCC24 Noemi Reguart performs a deep dive analysis on a hard topic and an unmet medical need: New molecular targets for squamous NSCLC:

⚡️Actionable RTK alterations
⚡️Early-phase FGFR inhibitors
⚡️2nd gen PRMT5 inhibitors
⚡️BET/NSD3 inh
⚡️PD1/VEGF Bites
⚡️Biomarkers lacking!…

So happy to be in Prague today for a fantastic session on lung cancer screening and prevention #ELCC24 ESMO - Eur. Oncology IASLC .
Very proud to be on stage with giants in this field, my colleagues Laura Mezquita and Lecia Sequist, MD, MPH .
#TeamHCL HCL - Hospices Civils de Lyon

#ELCC24 : Lung Cancer new pathways, including FGFR nicely presented by Noemi Reguart from Hospital Clínic 🫁🧬🩺 ESMO - Eur. Oncology

#ClinicCancerCenter

My career started in ELCC where I had my first poster and my first oral communication! At the time was a small congress in Geneva, now it is a big reality and still represents a wonderful opportunity for youngs and ‘differently youngs’ 🤣 #ESMOAmbassadors #ELCC24 ESMO - Eur. Oncology